Moneycontrol Be a Pro
Get App
SENSEX NIFTY
YOU ARE HERE >  Moneycontrol Markets > Announcements PharmaceuticalsAnnouncement - Fresenius Kabi
Fresenius Kabi
BSE: 532545NSE: FKONCOISIN: INE575G01010

1st-Nov-2013 12:39Source: BSE

Fresenius Kabi - Post Delisting Offer

DSP Merrill Lynch Ltd ("Manager to the Delisting Offer") on behalf of Fresenius Kabi (Singapore) Pte Ltd (“Acquirer”) has informed this Post Offer Public Announcement ("Post Offer PA") to the Public Shareholders of the Fresenius Kabi Oncology Limited (“Company”). This Post Offer PA is in continuation of and should be read in conjunction with, (i) the public announcement published on September 16, 2013 (“PA”) in respect of the proposed acquisition by the Acquirer and consequent delisting of the fully paid-up equity shares of the company with a face value of Re. 1 each (“shares”) from the BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”) in accordance with the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009) ("Delisting Regulations”), and (ii) the letter of offer issued in respect thereof inviting Bids from all Public Shareholders of the company (“Letter of Otter”), as amended by the first corrigendum to the PA and the Letter of Offer published on October 13, 2013, the second corrigendum to the PA and the Letter of Offer published on October 19, 2013 and the supplement to the second corrigendum (to the PA and the Letter of Offer) published on October 22, 2013. This Post Offer PA is being issued in accordance with Regulation 18 of the Delisting Regulations.

The capitalised terms and abbreviations used in this Post Offer PA and not defined herein have the same meaning as ascribed to them in the PA and the Letter of Offer unless otherwise specified.

The Acquirer issued the PA seeking to acquire, in accordance with the Delisting Regulations, and on the terms and conditions set out therein and in the Letter of Offer, 30,063,255 Shares representing 19% of the total share capital of the company. Public Shareholders holding Shares were invited to submit Bids pursuant to the reverse book-building (“RBB”) process made available through the electronic system of the BSE during the Bid Period (October 23, 2013 to October 25, 2013), in accordance with the Delisting Regulations.

More Announcements on:

31st-Dec-2013 13:35Source: BSE

Fresenius Kabi - Exit Offer (Delisting)

30th-Dec-2013 13:27Source: NSE

Fresenius Kabi Oncology Limited

21st-Dec-2013 08:22Source: NSE

Fresenius Kabi Oncology Limited

21st-Dec-2013 08:19Source: NSE

Fresenius Kabi Oncology Limited

12th-Dec-2013 08:50Source: NSE

Fresenius Kabi Oncology Limited

11th-Dec-2013 21:38Source: BSE

Fresenius Kabi - Resignation of Director

1st-Nov-2013 12:39Source: BSE

Fresenius Kabi - Post Delisting Offer

31st-Oct-2013 13:09Source: NSE

Fresenius Kabi Oncology Limited

24th-Oct-2013 15:32Source: NSE

Fresenius Kabi Oncology Limited

1 2 3 4 5 Next >>
Sections
Follow us on
Available On